Planning a clinical performance study under IVDR in 2026 requires more than regulatory awareness, it requires strategic alignment with ISO 20916:2024.
This article breaks down what ISO 20916:2024 means in practice, how it interacts with IVDR, the key differences you must consider before designing your study, and how to position your project for regulatory success.
What changed with ISO 20916:2024 and how it affects your study strategy
ISO 20916:2024, Clinical performance studies using specimens from human subjects: Good study practice, was first introduced in 2019. In March 2024, it was published as EN ISO 20916:2024, marking a major step in ISO 20916 2024 IVDR harmonization IVD studiesacross Europe. This update aligns clinical performance study requirements directly with the IVDR.
In today’s rapidly evolving IVD landscape, safety and performance remain top priorities. ISO 20916 provides a solid framework to ensure clinical performance studies are planned, executed, recorded, and reported with scientific rigor. Its goal is simple: ensure IVD studies are ethical, reliable, and aligned with regulatory expectations.
This standard supports robust study design, promotes high‑quality data generation, and strengthens compliance for IVD manufacturers navigating the IVDR.
Planning a clinical performance study in 2026?
Request access to our expert session on preparing a GDD clinical performance study under ISO 20916:2024.
The Role of Annex ZA in IVDR Performance Studies
The March 2024 revision introduced a key milestone: Annex ZA, which formally harmonizes ISO 20916 with the IVDR. While the IVDR already referenced ISO 20916, the addition of Annex ZA creates a unified regulatory pathway for clinical performance studies.
Annex ZA bridges the remaining gaps between the standard and the regulation. As a result, manufacturers benefit from clearer expectations and a more predictable approval process.
EN ISO 20916:2024 was approved by CEN without modification, reinforcing its relevance for EU regulatory compliance. However, at the time of writing, official recognition of ISO 20916:2024 as an IVDR harmonized standard in the EU Official Journal is still pending.
Note: As of the date this article was written, the official recognition of ISO 20916:2024 as an IVDR harmonized standard for clinical performance studies in theEuropean Union’s Official Journal was awaiting confirmation.
How Annex ZA Connects ISO 20916:2024 with IVDR Requirements
1. Presumption of Conformity
Compliance with the ISO 20916 clauses listed in Table ZA.1 gives manufacturers a presumption of conformity with IVDR GSPRs. This presumption simplifies regulatory alignment across IVD clinical performance studies.
2. Definition Alignment
When definitions differ between ISO 20916 and the IVDR, Annex ZA prioritizes IVDR terminology. This ensures consistency across regulatory submissions.
3. Risk‑Management Updates
Annex ZA strengthens risk‑management expectations. It requires alignment with IVDR principles such as “reducing risks as far as possible.” It also notes that ISO 20916 does not include foreseeable misuse, while the IVDR does—requiring sponsors to bridge this gap.
4. Acceptable Risk Policies
Manufacturers must align acceptable risk decisions with specific GSPRs. Annex ZA also clarifies that while ISO 20916 excludes training as a risk‑reduction measure, the IVDR allows it.
ISO 20916 vs IVDR: A Practical Comparison for Study Design
| Topic | ISO 20916 | IVDR |
|---|---|---|
| Annex XIV studies | No specific terminology for surgically invasive sample taking | Recognizes surgically invasive sampling as Annex XIV study |
| Adverse events | Structured categorization (device-related / non-device-related, serious, anticipated) | Less prescriptive |
| CPSP | Detailed specimen requirements | Requires reference to state of the art |
| Monitoring | Prescriptive; allows rationale for remote monitoring | Requires independent monitor |
| Informed consent | Highly detailed framework | Less detailed |
Where ISO 20916 and IVDR Align
- Despite some differences, the ISO and IVDR frameworks remain closely aligned in key areas:
- Clinical performance parameters: Nearly identical, except ISO 20916 omits expected values for normal and affected populations.
- Ethical considerations: ISO 20916 provides more detail, defining responsibilities for sponsors and investigators.
- Bias mitigation: ISO 20916 offers explicit direction on preventing population, protocol, and reference‑method bias.
- Site qualification: More detailed under ISO 20916, specifying resources, equipment validation, and QMS expectations.
- CPSR content: ISO 20916 includes additional requirements, especially for interventional studies.
- Comparator devices: The standard requires clear listing with commercial name, manufacturer, and catalog number.
- Investigator’s Brochure: Both the IVDR and ISO 20916 are aligned, though ISO adds more detail on risk‑benefit documentation.
Who Should Apply EN ISO 20916:2024 in 2026?
- Manufacturers of in vitro diagnostic medical devices
- In vitro diagnostic clinics and laboratories
- Test centres for in vitro diagnostic medical devices
- Regulatory authorities
- IVDR Notified Bodies
- IVD Clinical research organizations (CROs)
- Investigators and sponsors
Advantages of Applying EN ISO 20916 in IVD Performance Studies
- Robust Results: It ensures high-quality, accurate, and reliable data generation, pivotal for safe healthcare decisions.
- Ethical Standards: It upholds the rights, safety, dignity, and well-being of study subjects.
- Study Planning and Conduct: It facilitates the meticulous planning and execution of IVD performance studies, ensuring regulatory and ethical compliance alongside scientific validity.
- Compliance and Clarity: It provides a framework for compliance with IVDR, clarifying roles and responsibilities of all parties involved.
- Risk Management: It emphasizes subject safety, especially regarding specimen collection risks, and ensures data integrity.
Implications for Sponsors and CROs Conducting IVD Performance Studies
The integration of ISO 20916 with the IVDR, highlighted by the inclusion of Annex ZA, significantly transforms IVD clinical performance studies and CRO operations. This crucial alignment demands a comprehensive revision in study design, execution, and reporting methodologies, highlighting the importance of compliance with the unified ISO 20916 and IVDR standards. It emphasizes the need for robust quality and risk management systems and ethically responsible study development.
This evolution signifies more than standard adherence; it represents a commitment to elevating IVD performance and efficacy in line with the highest EU regulatory standards. It requires IVD stakeholders, including CROs, sponsors and manufacturers, to deeply understand and agilely apply these standards, not only for compliance but to set new quality and safety benchmarks in diagnostics.
This commitment is fundamental to advancing patient care and public health, marking a significant step forward in regulatory compliance and industry excellence.
Since its foundation, MDx CRO has consistently used ISO 20916 as the benchmark for all our IVD clinical performance studies. The release of Annex ZA and its harmonization with IVDR reinforces our status as the leading CRO for IVD clinical performance studies.
Achieving Success in IVD Clinical Performance Studies
At MDx CRO, we navigate the complexities of IVDR and the latest ISO 20916 revision for in vitro diagnostic (IVD) studies with unmatched expertise. Our commitment to rigorous clinical operations ensures that every clinical performance study meets all regulatory standards, incorporating strategic risk management and adaptability for maximum compliance and integrity.
Partnering with us offers manufacturers a significant advantage, rigorously evaluating IVDs to ensure adequate performance and safety, a critical component of regulatory approvals.
Choose MDx CRO for excellence in IVD clinical performance studies, driving success and enhancing patient outcomes. Contact us for a discussion today!
Frequently Asked Questions about ISO 20916:2024 in 2026
ISO 20916:2024 provides a structured framework for the design, conduct, recording, and reporting of clinical performance studies involving IVD medical devices. While IVDR sets the legal requirements, ISO 20916 supports sponsors in demonstrating compliance through a harmonized and internationally recognized standard. Not all studies are identical in scope or risk level, but for interventional and other performance studies involving risk to subjects, alignment with ISO 20916 is strongly recommended to ensure methodological and documentation consistency.
Annex ZA explains the relationship between ISO 20916:2024 and the requirements of IVDR. It maps the clauses of the standard to the corresponding IVDR provisions, helping sponsors understand how applying the standard supports regulatory compliance. In practice, Annex ZA serves as a bridge between operational study conduct and regulatory expectations under IVDR.
In 2026, regulatory scrutiny around clinical evidence and performance data continues to increase. ISO 20916:2024 offers a structured and prescriptive framework that reduces ambiguity in study design, monitoring, and documentation. For sponsors, early alignment with ISO 20916 can help minimize deficiencies during review, improve study robustness, and support smoother interactions with Notified Bodies.
ISO 20916:2024 is not a regulation. IVDR is legally binding, whereas ISO 20916 is a standard. However, when recognized as harmonized, applying the standard provides a presumption of conformity with relevant IVDR requirements. Even where not mandatory, it is widely considered best practice for structuring clinical performance studies.
